OliX Pharmaceuticals Inc. announced the publication of preclinical research on the androgenetic alopecia (hair loss) treatment program, OLX104C, in Molecular Pharmaceutics. The Company is developing the treatment for androgenetic alopecia based on cell-penetrating asymmetric siRNA (cp-asiRNA) platform technology. OLX104C reduces the expression of androgen receptor (AR), one of the key factors that cause androgenetic alopecia, which results in the suppression of the hair cycle transition from anagen to telogen phase.